ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Biochemical Pharmacology
Volume 68, Issue 5, 1 September 2004, Pages 857-866
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (466 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
Special issue
View Record in Scopus
 
doi:10.1016/j.bcp.2004.05.023    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2004 Elsevier Inc. All rights reserved.

Cytotoxicity, DNA strand breakage and DNA–protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Nicholas Farrella, Lawrence F. Povirkb, Yojana Dangeb, Gerald DeMastersb, Mona S. Guptab, Glenda Kohlhagenc, Qasim A. Khanc, Yves Pommierc and David A. GewirtzCorresponding Author Contact Information, E-mail The Corresponding Author, b

a Department of Chemistry, Virginia Commonwealth University, P.O. Box 23284, 1001 W. Main St., Richmond, VA 23284-2006, USA

b Department of Pharmacology and Toxicology, Virginia Commonwealth University, P.O. Box 980230, 1101 East Marshall St., Richmond, VA 23298, USA

c Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA


Received 7 January 2004; 
accepted 11 May 2004. 
Available online 24 July 2004.

Abstract

Cisplatin, cis-[PtCl2(NH3)2], is commonly utilized in various combination chemotherapy protocols for the treatment of both ovarian and breast cancer while the corresponding trans isomer is therapeutically inactive. This work describes efforts to elucidate the cellular mechanism of action of a novel trans-platinum compound, trans-(dichloroamminethiazole)platinum(II) (ATZ), which demonstrates antiproliferative and cytotoxic effects against both MCF-7 human breast and A2780 human ovarian carcinoma cells in culture. A2780 cells were approximately twofold more sensitive to ATZ than MCF-7 cells in both cell growth and clonogenic survival assays. Dye exclusion studies revealed a 50–70% loss in cell viability within the first 12 h of drug treatment in both cell lines. This initial wave of cell death was succeeded by a prolonged interval of growth arrest during which a small fraction of apoptotic cells was detected. Binding of ATZ to DNA, as estimated by atomic absorption spectroscopy, was similar for the two cell lines and was almost completely reversed 24 h after drug removal. ATZ also induced DNA strand breakage as well as DNA–protein crosslinking during the initial 12 h period when the bulk of cell death was evident. However, neither the extent of DNA strand breakage nor that of DNA protein crosslinking was sufficient to explain the different drug sensitivity in the two cell lines. At 24 and 48 h after exposure of MCF-7 cells to high concentrations of ATZ, the formation of DNA-topoisomerase I complexes is detected, coincident with a high degree of apoptosis. These studies suggest that ATZ has the capacity to interfere with topoisomerase I in the tumor cell, a function not evident in cis-platinum-based drugs.

Author Keywords: DNA strand breakage; DNA–protein crosslinking; Novel transplatinum compound; Apoptosis; MCF-7; A2780

Article Outline

1. Introduction
2. Materials and methods
2.1. Materials
2.2. MTT dye assay for drug sensitivity
2.3. Clonogenic survival
2.4. DNA binding
2.5. Alkaline unwinding
2.6. Detection of apoptotic cells by TUNEL assay
2.7. β-Galactosidase histochemical staining
2.8. DNA–protein crosslinks
2.9. Detection of topoisomerase I-DNA complexes
3. Results
3.1. Growth inhibition, clonogenic survival and apoptosis
3.2. Senescence arrest
3.3. DNA damage
3.4. DNA–protein crosslinking
3.5. Formation of topoisomerase I-DNA complexes
4. Discussion
Acknowledgements
References








Corresponding Author Contact InformationCorresponding author. Present address: Department of Medicine, Virginia Commonwealth University, P.O. Box 980230, 1101 East Marshall St. , Richmond, VA 23298, , USA. Tel.: +1 804 828 9523; fax: +1 804 828 8079.


Biochemical Pharmacology
Volume 68, Issue 5, 1 September 2004, Pages 857-866
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.